Middle East & Africa Antibiotics & Antimycotics Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The antibiotics and antimycotics market in the Middle East and Africa is projected to grow significantly, reaching approximately USD 2,187.95 million by 2031, up from USD 1,756.67 million in 2023, reflecting a compound annual growth rate (CAGR) of 2.8% from 2023 to 2031.

Executive Summary and Market Analysis

The market is divided into key regions: Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East and Africa. Several factors are propelling market growth, including the rising incidence of infectious diseases caused by bacteria and fungi, strategic initiatives by industry players such as new product launches and partnerships, and supportive government policies. Additionally, the geographical expansion of market participants and increasing awareness regarding the appropriate use of antibiotics and antimycotics are expected to further stimulate market growth in the upcoming years.

Market Segmentation Analysis

The Middle East and Africa antibiotics and antimycotics market is categorized based on drug class, indication, route of administration, and distribution channel:

Drug Class: The market includes various drug classes such as penicillin, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, penicillin dominated the market share.
Indication: The market is segmented into skin infections, respiratory infections, urinary tract infections (UTI), septicemia, ear infections, gastrointestinal infections, and others. Respiratory infections held the largest market share in 2023.
Route of Administration: This includes oral, topical, and other methods, with oral administration being the most prevalent in 2023.
Distribution Channel: The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies capturing the largest share in 2023.

Market Outlook

Infectious diseases, caused by various pathogens including bacteria and fungi, pose significant health challenges. According to a 2022 report by ReAct Group, bacterial infections were linked to 77 million deaths globally, excluding tuberculosis, which ranks as the 13th leading cause of death worldwide. The World Health Organization (WHO) reported that tuberculosis (TB) was responsible for 1.3 million deaths in 2022, with a significant number of new cases arising in high-burden countries.

Healthcare-associated infections (HAIs) also contribute to high morbidity and mortality rates, imposing substantial costs on healthcare systems. Common antibiotics prescribed for conditions like hospital-acquired diarrhea and urinary tract infections include metronidazole, vancomycin, ofloxacin, ceftriaxone, and amoxicillin.

Moreover, the rise in fungal infections is a growing concern, with the Global Action Fund for Fungal Infections (GAFFI) estimating that over 80 million people are at high risk of developing fungal diseases annually, leading to approximately 6.55 million cases of life-threatening infections and 3.75 million deaths. Azoles and Amphotericin B are frequently used antimycotics for treating these infections. The increasing prevalence of bacterial and fungal infections underscores the urgent need for effective antibiotics and antimycotics.

Country Insights

The market analysis by country reveals that Saudi Arabia held the largest share in 2023. The growth in Saudi Arabia's antibiotics and antimycotics market is driven by rising healthcare expenditures, a growing prevalence of infectious diseases, and ongoing health initiatives aimed at combating antibiotic resistance. UTIs are notably common, accounting for 10% of all infections in the country, while the prevalence of tuberculosis is reported at 17%, exceeding the global average.

Recent product innovations, such as the launch of STIMULAN by Biocomposites in October 2023, which serves as an antibiotic carrier for wound healing, are expected to enhance market opportunities in Saudi Arabia.

Company Profiles

Key players in the antibiotics and antimycotics market include Pfizer Inc., Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc., GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc., and Astellas Pharma Inc. These companies are pursuing various strategies, including market expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase market share.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa antibiotics & antimycotics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa antibiotics & antimycotics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the antibiotics & antimycotics market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution. Show more